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DeliriumAbstract Objective: To report about delirium related to Cycloserine.
Method: Systematic assessment and management of a patient who developed delirium during the
course of treatment for MDR-TB.
Results: An association was found with the use of Cycloserine and development of delirium. The
management of this case is described.
Conclusion: Patients with MDR-TB receiving Cycloserine should be closely monitored for neu-
ropsychiatric side effects for early recognition and treatment.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Regimens used for MDR-TB have been reported to cause
more adverse effects than the ﬁrst-line agents, with treatment
discontinuation rates of 19–55% [1–5]. Cycloserine is a broad
spectrum antibiotic and has been classiﬁed by WHO as a sec-
ond-line group IV oral bacteriostatic drug used in a dose of250–500 mg twice daily. Cycloserine does not share cross resis-
tance with other anti-mycobacterial agents and hence is used
for drug-resistant cases. Adverse effects of Cycloserine are
mainly dose-related [6]. Psychiatric adverse events such as anx-
iety, hallucinations, depression, euphoria, behavioural changes
and suicidality have been reported in 9.7–50% of individuals
while on Cycloserine [7]. These side effects are most likely to
occur during the ﬁrst 3 months of treatment.
Report
A 72 year old lady, diagnosed as MDR-TB, admitted in the
inpatient services of a regional chest institute was referred by
the chest physician to the consultation liaison psychiatry team,
with symptoms of being withdrawn and apathetic. Theserculosis.
450 G. Saraf et al.symptoms were noted around 7 days following the intake of
Cycloserine 500 mg OD. Subsequently, Cycloserine was
stopped for a week due to these side effects, and the symptoms
improved. A re-challenge of Cycloserine with the same dosage
was attempted after a gap of a week that resulted in patient
again developing similar psychiatric symptoms. On detailed
evaluation, patient’s relatives reported history of confusion,
disturbed sleep, disorientation to time, calling out people’s
names and not recognising relatives which would worsen in
the night in addition to the above symptoms. She had also
shaved off her hair in the night on one occasion and did not
provide any explanation for the same.
She did not have any past history of a psychiatric illness
and her baseline investigations at admission to the hospital
including electrolytes, complete blood count and ECG were
within normal limits.
On examination, she was noticed to be disoriented to place
and time, with ﬂuctuating orientation for person and reported
of perceptual disturbances in the form of visual hallucinations.
Review of drug chart revealed that the MDR-TB regimen con-
sisted of Kanamycin, Oﬂoxacin, Levoﬂoxacin, Cycloserine,
Ethionamide, Pyrazinamide, Ethambutol and Pyridoxine.
A clinical diagnosis of Cycloserine induced delirium was
considered and Cycloserine was replaced with Para amino sal-
icylic acid by the Chest Physician. The delirium was treated
with Quetiapine 25 mg BD along with behavioural measures
and suitable environmental modiﬁcations. A signiﬁcant
improvement in orientation and sleep was noted within 3 days.
Subsequently, she had an episode of diarrhoea, which led to a
worsening of delirium. Serum electrolytes were deranged
(Sodium-128 mEq/L, Potassium-3.1 mEq/L, Chloride-
105 mEq/L) and suitable correction was started by the physi-
cian. However, the delirium continued to worsen despite
receiving Quetiapine, hence Risperidone 0.5 mg at night was
added. She developed slurring of speech with the same and
hence Risperidone was stopped. In view of worsening delirium,
Quetiapine was stopped and Olanzapine 2.5 mg BD was
started. Her repeat electrolytes continued to be deranged.
Olanzapine was increased to 2.5 mg in the morning and 5 mg
in the night, with which sleep and oral intake slightly got bet-
ter. A week after this, patient started becoming withdrawn,
unresponsive, refused to take orally. Resuscitation failed and
patient succumbed to hypovolemic shock 4 days later.
Discussion
Drug regimens for MDR-TB use agents in combination that
are more toxic than the ﬁrst-line drugs. Further, some anti-
tuberculosis drugs used in second-line regimens for drug resis-
tant tuberculosis also potentiate the toxicity of other agents
used in the regimen [1]. Psychiatric adverse effects are known
in the treatment of tuberculosis and are associated with
increased mortality and unfavourable prognosis [8]. There
have been case reports of Cycloserine induced mania [9] and
psychosis [10], however to the best of our knowledge, none
reported on delirium so far.
In this patient, the score on Naranjo ADR probability scale
was 5 which suggests probable association [9]. She also was on
a combination of drugs which are known to cause psychiatric
side effects such as Fluoroquinolones. The recurrence of
symptoms after a rechallenge with Cycloserine further goesin favour of Cycloserine induced mental state changes. How-
ever, the patient deteriorated again due to the development
of diarrhoea and electrolyte disturbances.
Cycloserine has been implicated to cause elevation of GABA
due to inhibition of GABA transferase in studies on mice [11].
GABA has been implicated in delirium [12], with studies suggest-
ing that GABA activity is increased in delirium due to hepatic
encephalopathy and decreased in that caused by hypnotic/
sedative withdrawal [13]. Glutamate is another neurotransmitter
that has been researched in the pathogenesis of delirium [14,15].
Cycloserine also has effects on glutamatergic transmission
through its actions on AMPA/Kainate and NMDA receptors
[16]. Thus it can be hypothesised that Cycloserine could have
caused delirium due to its actions on the GABA and glutamate
neurotransmitter system. However, other factors that might
have exacerbated/precipitated delirium are elderly age,
diarrhoea, electrolyte imbalance and concurrent medications
such as Fluoroquinolones. This mechanism is a possible cause
of Cycloserine induced delirium in the current case; however, this
could not be conﬁrmed biochemically. There could be other
unknown mechanisms, which are difﬁcult to speculate.
This case illustrates the need for close monitoring of psychi-
atric adverse events in patients receiving regimens for MDR
TB. This must also be followed by a thorough evaluation of
other confounding factors that might lead to a similar clinical
picture. As multi-drug resistance becomes more prevalent,
there is a need for close liaison between chest physicians and
psychiatrists to ensure prompt addressal of these adverse
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